EyePoint (EYPT) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed EyePoint (EYPT) over the past year, losing 22.4% versus a loss of 75.1%. Over five years, EYPT leads with a -69.8% price change compared with -90.6% for RCKT. EyePoint is the larger company by market cap ($285.1 million vs $281.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | RCKT |
|---|---|---|
| Share price | $3.40 | $2.56 |
| Market cap | $285.06M | $281.02M |
| 1-day change | -1.73% | -2.66% |
| YTD return | -81.06% | -25.07% |
| 1-year return | -75.07% | -22.42% |
| 5-year return | -69.76% | -90.58% |
| EPS (TTM) | $-3.75 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $5.45 |
| 52-week low | $3.05 | $2.42 |
| Distance from 52-week high | -82.21% | -53.03% |
| Analyst consensus | none | buy |
| Avg. price target upside | +662.06% | +232.03% |
| Average volume | 3.96M | 1.67M |
| Shares outstanding | 83.84M | 109.77M |
| Employees | 214 | 202 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed EYPT by 52.7 percentage points over the past year.
- The two companies sit in different sectors: EyePoint in Industrials and Rocket Pharmaceuticals in Health Care.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
EYPT vs RCKT FAQ
Which is bigger, EyePoint or Rocket Pharmaceuticals?
EyePoint (EYPT) is larger, with a market capitalization of $285.06M compared with $281.02M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, EYPT or RCKT?
RCKT returned -22.42% over the past 12 months, compared with -75.07% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Rocket Pharmaceuticals in the same industry?
No. EyePoint is in the Industrials sector, while Rocket Pharmaceuticals is in Health Care.